This post was published byJon Fleetwood.Support him by subscribing atSubstackand following atInstagram/X/Facebook.
In a major acceleration of bird flu pandemic orchestration and mass vaccination infrastructure, Moderna, Inc. yesterdayannouncedthat “the first participants in the U.S. and UK have been dosed in a Phase 3 study of the Company’s investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018.”
This is the first mRNA-based pandemic influenza (H5 bird flu) vaccine to reach Phase 3 clinical trials anywhere in the world.
The move comes after President Donald Trumpselecteda military influenza pandemic policy architect—Dr. Erica Schwartz, who built and enforced surveillance, vaccination, and compliance systems—to take control of the CDC.
Signalling its high confidence that there will be future demand for influenza vaccines, Modernaannouncedon the same day that another of its influenza jabs, mCOMBRIAX® (mRNA-1083), has been granted marketing authorization by the European Commission (EC).
Moreover, the Trump administration is currentlyfundinggain-of-function experiments on influenza pathogens.
Just as coronavirus gain-of-function experiments and vaccine development (the problem and the solution) were simultaneously carried out before the COVID-19 pandemic, the same dual-track approach is now being applied to influenza—advancing high-risk pathogen work in parallel with the rapid rollout of mRNA vaccine platforms designed to respond to it.
Moderna’s Tuesday press release reveals that 4,000 adults will be injected with the bird flu shot:
The Phase 3 study will evaluate the safety and immunogenicity of mRNA-1018 in healthy adults ages 18 years and older and is expected to enroll approximately 4,000 adults in the U.S. and UK. If successful, global regulatory submissions for mRNA-1018 will be further supported by positive data from the pivotal Phase 3 trial of Moderna’s investigational seasonal influenza vaccine, mRNA-1010, which has been accepted for review in the U.S., the European Union, Canada and Australia.
In December 2025, this website was thefirst to reportthat Bill Gates’ vaccine cartel, the Coalition for Epidemic Preparedness Innovations (CEPI), had invested $54.3 million to help advance mRNA-1018 to licensure.
Source: modernity
